Stryker Corp. SYK
Spruce Point exposes Stryker's FCPA-tainted accounting, failing acquisition roll-up and margin squeeze under CEO Lobo — Strong Sell with 35%-75% downside to $67-$174.50.
Thesis
After a forensic investigation of Stryker Corp (NYSE: SYK), Spruce Point concludes the $118bn S&P 500 medical-device roll-up is trapped in a margin squeeze while covering up inventory, goodwill and depreciation problems. Under CEO Kevin Lobo and CFO Glenn Boehnlein — leading one of few public companies charged twice by the SEC for FCPA violations — Stryker has amassed $16bn of debt, $18bn of goodwill and a string of failing acquisitions including Vocera ($3.1bn, argued write-down to zero), Wright Medical, K2M, Mako and OrthoSensor. Widening GAAP vs. Non-GAAP metrics, abandoned ROIC disclosure, suspect contingent-payment accounting and two sets of D&A figures all point to management delaying bad news. Spruce Point calls on the Audit Committee to retain an independent forensic investigator, for Lobo and Boehnlein to resign, and models 35%-75% downside to $67-$174.50 per share.
SCQA
Stryker is a $118bn S&P 500 medical-device roll-up trading near peak 6.5x sales and 35x EBITDA, viewed by sell-side as a premium orthopedic and surgical acquirer with consistent ROIC and margin expansion.
Forensic probe uncovers two SEC FCPA settlements, $15bn+ debt, inventory step-ups, goodwill that never impairs, abandoned ROIC disclosure, widening GAAP vs. Non-GAAP, and serial overpayment for failing targets (Vocera, Wright, K2M, Mako, OrthoSensor).
Calls for CEO Lobo and CFO Boehnlein to resign, Audit Committee to hire an independent forensic investigator, new auditor, goodwill impairments, halting acquisitions, completing the $1bn ERP, and rationalizing 50+ manufacturing sites.
35%-75% downside to $67-$174.50 per share (-34% to -72%) as Stryker's peak 6.5x sales / 35x EBITDA / 43x OCF multiples compress toward medical-device peers such as Zimmer Biomet and Smith & Nephew.
The three reasons
- 1
$16bn debt-fueled roll-up is failing — Vocera, Wright Medical, K2M, Mako acquisitions deteriorating
- 2
Forensic review flags suspect inventory step-ups, hidden contingent payments and two sets of D&A figures
- 3
35%-75% downside to $67-$174.50 as peak 35x EBITDA multiple compresses toward Zimmer/Smith & Nephew peers
Primary demands
- Replace CEO Kevin Lobo and CFO Glenn Boehnlein
- Audit Committee (led by HBS Dean Srikant Datar) to retain an independent forensic investigator
- Hire a new auditor (Ernst & Young continuous since 1974)
- Impair goodwill on failed acquisitions (K2M, STAR Ankle, Spine)
- Cease debt-fueled acquisition strategy and refocus on internal investment, Capex and debt reduction
- Rationalize manufacturing footprint (50+ facilities) and complete the failed ERP project
- Reset long-term growth and margin expansion targets
KPIs cited
Pattern membership
Precedents cited
- Spruce Point's 2017 short on TSO3 (TSX: TOS) — 84% decline, later acquired by Stryker
- Spruce Point's 2018 short on Maxar Technologies (NYSE/TSX: MAXR) — 90% decline, advised by former Stryker director Howard Lance
- Spruce Point's 2021 short on Heska (Nasdaq: HSKA)
- Spruce Point's S&P 500 shorts: Church & Dwight (CHD 2019), AMETEK (AME 2014), Mettler-Toledo (MTD 2019), A.O. Smith (AOS 2019)
- K2M management's prior InPhonic accounting scandal
Composition what's on the 195 slides
Slide gallery ·
Notes
Short-seller research report by Spruce Point Capital (founder Ben Axler quoted directly on p.4; Ben Axler is the primary named author). Branded 'Stryke Three You're Out — Strong Sell Opinion'. Signature Spruce Point teal-on-grey template with red-flag icon on every thesis slide, yellow callout boxes, and highlighted quotes from former-employee interviews and peer management calls. Heavy on forensic accounting evidence: two sets of D&A figures, inventory step-ups, missing contingent payments, abandoned ROIC disclosure, widening GAAP vs. Non-GAAP. 195-page deck; sampled ~25 pages across cover, track record, executive summary, acquisition post-mortems, peer comparables and valuation sections. No explicit stake percentage disclosed beyond the boilerplate short-position statement in the legal disclaimer.